Horizon Europe is the European Union (EU) funding programme for the period 2021 – 2027, which targets the sectors of research and innovation. The programme’s budget is around € 95.5 billion, of which € 5.4 billion is from NextGenerationEU to stimulate recovery and strengthen the EU’s resilience in the future, and € 4.5 billion is additional aid.
Framework Partnership Agreements (FPAs) respectively for open testing, experimentation, and for pilot production capabilities for quantum technologies are expected to establish stable and structured partnerships between the Commission and the institutions and organisations. Proposals are expected to establish well-networked lab facilities that interact and support each other.
Proposals should federate key competences in the whole innovation value chain, from business-model development to promoting open-access to innovation and know-how, in order to provide access and support to European quantum technologies innovation actors. Proposals should develop practical strategies in synergy with European academic and industrial players (especially start-ups and SMEs), and quantum technologies innovation actors in Europe to provide the quantum ecosystem with a ‘one-stop-shop’ to unique facilities, competences and know-how centred at various locations in Europe.
The consortia applying for the first FPA should include a balanced and inclusive network of RTOs and other excellent European institutes equipped with state of the art quantum experimental facilities, infrastructures and tools, and other key innovation players that can play a role in the implementation of sustainable open experimental and testing infrastructures in quantum technologies. The consortia applying for the second FPA should include a balanced and inclusive network of RTOs and other excellent European institutes, small foundries, unique manufacturing providers, and other key innovation players that can play a role in building and providing experimental pilot production capabilities for quantum technologies.
Participation is limited to:
Legal entities established in Member States, Iceland, Norway, Israel and the United Kingdom. The eligibility of entities established in the UK to participate is conditional upon reciprocity of access to equivalent UK programmes for entities established in Member States, which will be assessed by the Commission as soon as such programmes are established and in any event before the signature of the grant agreements. Should the UK not open the participation in its relevant programmes to entities established in Member States, this condition would not be met and entities established in the UK will not be eligible to participate in this topic.
(further details in the work program)
Research and Innovation Foundation
29a Andrea Michalakopoulou Street, 1075 Nicosia
T.Th. 23422, 1683 Nicosia
+357 22205000
Email: support@research.org.cy
Dr Angelos Ntantos
Scientific Officer
Telephone: 35722205033
Email: antantos@research.org.cy
Dr Ioannis Theodorou
Scientific Officer
Telephone: 35722205038
Email: itheodorou@research.org.cy
(Publish Date: 02/12/2021-for internal use only)
Εuropean Commission, Directorate-General for Research and Innovation
https://ec.europa.eu/info/departments/research-and-innovation_en#contact